Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)
| General Information of Drug (ID: DR2437) | ||||||
|---|---|---|---|---|---|---|
| Drug Name |
Trimetazidine dihydrochloride
|
|||||
| Synonyms |
Trimetajust; Trimetazidine (dihydrochloride); Trimetazidine DiHCl; Trimetazidine HCl; Trimetazidine dihydrochloride; Trimetazidine hydrochloride; Kyurinett; Lubomail; Piperazine, 1-(2,3,4-trimethoxyb; S 4004; Vastarel; W-108326; Yosimilon; 1-(2,3,4-Trimethoxybenzyl)piperazine dihydrochloride; 1-[(2,3,4-trimethoxyphenyl)methyl]piperazine dihydrochloride; 13171-25-0; 48V6723Z1P; DSSTox_CID_25407; DSSTox_GSID_45407; DSSTox_RID_80858; EINECS 236-117-0; Piperazine, 1-[(2,3,4-trimethoxyphenyl)methyl]-, dihydrochloride; UNII-48V6723Z1P
|
|||||
| Indication | Atherosclerosis [ICD11: BA80] | Phase 4 | [1] | |||
| Structure |
![]() |
|||||
| 3D MOL is unavailable | 2D MOL | |||||
| Pharmaceutical Properties | Molecular Weight | 339.3 | Topological Polar Surface Area | 43 | ||
| Heavy Atom Count | 21 | Rotatable Bond Count | 5 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 5 | |||
| Cross-matching ID |
|
|||||
| The Metabolic Roadmap of This Drug | |||||
|---|---|---|---|---|---|
| The Full List of Drug Metabolites (DM) of This Drug | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
||||||||||||||||||||||||||||
| References | ||||||
|---|---|---|---|---|---|---|
| 1 | ClinicalTrials.gov (NCT02107144) The ImPact of Trimetazidine on MicrOcirculation After Stenting for Stable Coronary Artery Disease | |||||
| 2 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||||
| 3 | Identification of trimetazidine metabolites in human urine and plasma | |||||
| 4 | Doping control analysis of trimetazidine and characterization of major metabolites using mass spectrometric approaches | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.


